



US005534545A

United States Patent [19]

[11] Patent Number: **5,534,545**

Kilbourn et al.

[45] Date of Patent: **Jul. 9, 1996**

[54] **PARENTERAL AMINO ACID FORMULATIONS FOR THE INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION**

[75] Inventors: **Robert G. Kilbourn**, Houston, Tex.; **Owen W. Griffith**; **Steven S. Gross**, both of New York, N.Y.

[73] Assignees: **Board of Regents, The University of Texas System**, Austin, Tex.; **Cornell Research Foundation, Inc.**, Ithaca, N.Y.

[21] Appl. No.: **152,050**

[22] Filed: **Nov. 12, 1993**

Related U.S. Application Data

[62] Division of Ser. No. 767,265, Sep. 27, 1991, Pat. No. 5,286,739.

[51] Int. Cl.⁶ **A61K 31/195**; A61K 31/385; A61K 31/40

[52] U.S. Cl. **514/565**; 514/560; 514/561; 514/562; 514/564; 514/567; 514/400; 514/423; 514/419

[58] Field of Search 514/560, 565, 514/561, 562, 419, 400, 423, 567, 564

References Cited

[56]

U.S. PATENT DOCUMENTS

3,950,529	4/1976	Fischer et al.	424/273
4,734,420	3/1988	Ryan et al.	514/362
4,859,452	8/1989	Ajani et al.	424/10
4,988,724	1/1991	Ajani et al.	514/399
5,006,559	4/1991	Askanazi et al.	514/561
5,028,627	7/1991	Kilbourn et al.	514/565
5,036,052	7/1991	Ozeki et al.	514/19
5,059,712	10/1991	Griffith	562/560
5,132,453	7/1992	Griffith	562/560
5,158,883	10/1992	Griffith	435/240.2
5,162,373	11/1992	Ajani et al.	514/564
5,189,025	2/1993	Ajani et al.	514/565
5,216,025	6/1993	Gross et al.	514/565
5,286,739	2/1994	Kilbourn et al.	514/400

FOREIGN PATENT DOCUMENTS

0318446A1	5/1989	European Pat. Off.
2516027	10/1975	Germany
WO91/84023	4/1991	WIPO
WO91/04024	4/1991	WIPO

OTHER PUBLICATIONS

Remington's Pharmaceutical Sciences, Fifteenth Edition, Mack Publishing Company, (1976).
 Kilbourn et al., (1990), *Journal Nat'l Cancer Inst.*, 82(9):772-776.
 Kilbourn et al., (May 1990), *Proc. Natl. Acad. Sci. USA*, 87:3629-32.
 Sakuma et al., (1988), *Proc. Natl. Acad. Sci. USA*, 85:8664-67.
 Stuehr et al., (1989), *J. Exp. Med.*, 169:1011-20.
 Hibbs et al., (1988), *Biochem Biophys. Res. Comm.* 157(1):87-94.

Stuehr et al., (1987), *J. Immunology*, 139:518-525.
 Palmer et al., (1987), *Nature*, 327:524-526.
 Natanson et al. (1989), *J. Exp. Med.*, 169:823-832.
 Starnes et al. (1988), *J. Clin. Invest.*, (82(4):1321-25.
 Nathan et al., (1991) *Journal Natl Cancer Inst. (USA)*, 82(9):726-28.
 Schmidt et al., (1988), *European J. of Pharmacology*, 154:213-216.
 Moncada et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," *Pharmacological Reviews*, 43(2):109-142, 1991, published in USA.
 Moncada et al., "The L-Arginine: Nitric Oxide Pathway," *Journal of Cardiovascular Pharmacology*, 17(Suppl. 3):S1-S9, 1991, published in USA.
 Parratt, J. R., and Stoclet, Jean-Claude, "Possible Role of Nitric Oxide in Refractory Hypotension Associated with Sepsis and Endotoxaemia and with Multiple Organ Failure," *Applied Cardiopulmonary Pathophysiology*, 4:143-149, 1991, published in USA.
 Johnston, Jeff, "Molecular Science Sets Its Sights On Septic Shock," *The Journal of NIH Research*, 3:61-65, 1991, published in USA.
 Moncada, S., and Higgs, E. A., "Endogenous Nitric Oxide: Physiology, Pathology and Clinical Relevance," *European Journal of Clinical Investigation*, 21:361-374, 1991, published in Europe.
 Martin et al., "Selective Blockade of Endothelium-Dependent and Glyceryl Trinitrate-Induced Relaxation by Hemoglobin and by Methylene Blue in the Rabbit Aorta," *The Journal of Pharmacology and Experimental Therapeutics*, 232(3):708-716, 1985, published in USA.
 Buga et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," *European Journal of Pharmacology*, 161:61-72, 1989, published in Europe.
 Stuehr et al., "Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cytosol: Requirement for Inducible and Constitutive Components," *Biochemical and Biophysical Research Communications*, 161(2):420426, 1989, published in USA.

(List continued on next page.)

Primary Examiner—T. J. Criares
 Attorney, Agent, or Firm—Arnold, White & Durkee

[57] ABSTRACT

An anti-hypotensive formulation comprising an essentially arginine-free or low arginine (less than about 0.1%, most preferably, about 0.01%) containing mixture of amino acids is provided. The invention in particular embodiments of the anti-hypotensive formulation includes ornithine, citrulline or both. A method for prophylaxis and treatment of systemic hypotension in an animal is provided. Most particularly, a method for treating hypotension caused by nitric oxide synthesis through administering a low or essentially arginine-free parenteral formulation to an animal, so as to reduce or eliminate nitric oxide synthesis is described. A method for treating an animal in septic shock is also disclosed, comprising administering to the animal an anti-hypotensive formulation comprising a mixture of amino acids, which is essentially arginine free.

6 Claims, No Drawings